177Lu-labeled-VG76e monoclonal antibody in tumor angiogenesis: A comparative study using DOTA and DTPA chelating systems

Radiochimica Acta

Volumn 95, Issue 6, 2007, Pages 351-357

  Fani, M ^a,b   Bouziotis, P ^a   Harris, A L ^c   Psimadas, D ^a,b   Gourni, E ^a   Loudos, G ^d   Varvarigou, A D ^a   Maecke, H R ^e  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b Biomedica Life Sciences SA   (Greece)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Angiogenesis; DOTA; DTPA; Lutetium 177; Monoclonal antibodies; VEGF

Indexed keywords

EID: 34250774439     PISSN: 00338230     EISSN: None     Source Type: Journal    
DOI: 10.1524/ract.2007.95.6.351     Document Type: Article

References (25)

1. Folkman, J.: Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med. 1, 27 (1995).
2. Carmeliet, P., Jain, R. K.: Angiogenesis in cancer and other diseases. Nature 407, 249 (2000).
3. Fox, S. B., Gasparini, G., Harris, A. L.: Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2, 278 (2001).
4. Cross, M. J., Claesson-Welsh, L.: FGF and VEGF function in angiogenesis: signaling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22, 201 (2001).
5. Ferrara, N.: VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2, 795 (2002).
6. Ferrara, N., Hillan, K. J., Novotny, W.: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Comm. 333, 328 (2005).
7. Midgley, R., Kerr, D.: Bevacizumab-current status and future directions. Ann. Oncol. 16, 999 (2005).
8. Fraser, H. M., Dickson, S. E., Lunn, S. F., Wulff, C., Morris, K. D., Carroll, V. A., Bicknell, R.: Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 141, 995 (2000).
9. 124I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res. 62, 5912 (2002).
10. Bouziotis, P., Fani, M., Archimandritis, S. C., Loudos, G., Paravatou, M., Bicknell, R., Harris, A. L., Xanthopoulos, S., Stratis, N., Varvarigou, A. D.: Samarium-153 and technetium-99m-labeled monoclonal antibodies in angiogenesis for tumor visualization and inhibition. Anticancer Res. 23, 2167 (2003).
11. Liu, S., Edwards, D. S.: Bifunctional chelators for therapeutic lan-thanide radiopharmaceuticals. Bioconjug. Chem. 12, 7 (2001).
12. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies. Bioconjug. Chem. 9, 773 (1998).
13. 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J. Nucl. Med. 46, 1898 (2005).
14. Stimmel, J. B., Stockstill, M. E., Kull Jr., F. C.: Yttrium-90 chelation properties of tetraazatetraacetic acid macrosysles, diethylenetriaminepentaacetic acid analogues, and a novel terpyridine acyclic chelator. Bioconjugate Chem, 6, 219 (1995).
15. 177Lu for radioimmunotherapeutic applications. Nucl. Med. Biol. 29, 431 (2002).
16. 90Y-DTPA-Anti-CEA Mabs in nude mice bearing human colorectal cancer. J. Nucl. Med. 41, 337 (2000).
17. Li, W. P., Ma, D. S., Higginbotham, C., Hoffman, T., Ketring, A. R., Cutler, C. S., Jurisson, S. S.: Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl. Med. Biol. 28, 145 (2001).
18. 153Sm-labeled anti-CEA monoclonal antibody for radioimmunoscintigraphy and radioimmunotherapy. Anticancer Res. 23, 2195 (2003).
19. 186Re. J. Nucl. Med. 45, 327 (2004).
20. McMurry, T. J., Pippin, C. G., Wu, C., Deal, K. A., Brechbiel, M. W., Mirzadeh, S., Gansow, O. A.: Physical parameters and biological stability of yttrium(III) diethylenetriaminepentaacetic acid derivative conjugates. J. Med. Chem. 41, 3546 (1998).
21. Kobayashi, H., Wu, C., Yoo, T. M., Sun, B. F., Drumm, D., Pastan, I., Paik, C. H., Gansow, O. A., Carrasquillo, J. A., Brechbiel, M. W.: Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. J. Nucl. Med. 39, 829 (1998).
22. Roselli, M., Milenic, D. E., Brechbiel, M. W., Mirzadeh, S., Pippin, C. G., Gansow, O. A., Colcher, D., Schlom, J.: In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts. Cancer Biother. Radiopharm. 14, 209 (1999).
23. Oriuchi, N., Higuchi, T., Hanaoka, H., Iida, Y., Endo, K.: Current status of cancer therapy with radiolabeled monoclonal antibody. Ann. Nucl. Med. 19, 355 (2005).
24. Sharkey, R. M., Goldenberg, D. M.: Prespectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 46, 115S (2005).
25. Szilágyi, E., Tóth, E., Kovács, Z., Platzek, J., Radüchel, B., Bücher, E.: Equilibria and formation kinetics of some cyclen derivative complexes of lanthanide. Inorg. Chim. Acta 298, 226 (2000).